Worth reading
55In focus
Scored from 4 of 5 sectionsDirection
Neutral
Direction inferred from the company’s description.Scale
2125
USD millionWording
Definitive
How definitive the wording is.This transaction
Conversion of ViiV Healthcare Ltd. into an associate accounted for under the equity method through an additional investmentCounterparty (target company)ViiV Healthcare Ltd.
Disclosing companyShionogi & Co.,Ltd.
The voting-rights ratio is the share of the votes exercisable at a shareholders’ meeting that will be held after this transaction.The percentage before the change is not stated in this document.
Execution Date / Effective Date1 April 2026 (completed)
Target company
Location London, United Kingdom
Consideration and expenses
Acquisition priceUS$2,125 million
Type of ConsiderationAcquisition of newly issued shares in ViiV through a cash investment
| Item | Details |
|---|---|
| Transaction name | Conversion of ViiV Healthcare Ltd. into an associate accounted for under the equity method through an additional investment |
| Counterparty name | ViiV Healthcare Ltd. |
| Name of the Subject Company | ViiV Healthcare Ltd. |
| Location of the Subject Company | London, United Kingdom |
| Acquisition price | US$2,125 million |
| Type of Consideration | Acquisition of newly issued shares in ViiV through a cash investment |
| Voting rights ownership percentage | After 21.7% (before not disclosed) |
| Execution Date / Effective Date | 1 April 2026 (completed) |
Items this document does not state (24)
Business Description of the Subject CompanyCapital Stock of the Subject CompanyDate of Establishment of the Subject CompanyNet Sales of the Subject CompanyOperating Profit of the Subject CompanyNet Income of the Subject CompanyNet Assets of the Subject CompanyExpenses other than the acquisition priceMerger ratio/share exchange ratioTender offer priceMinimum number of shares to be purchasedTender offer periodNumber of shares acquiredFunding arrangementsGoodwill amountAmount of extraordinary income (loss)Impact on Business PerformanceDate of board resolutionContract DateValuation methodologyIndependent valuation institutionSpecial CommitteeConditions Precedent to ExecutionManagement structure after acquisition
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Shionogi & Co., Ltd. explained that it would further deepen its partnership with ViiV and GSK to address the unmet needs of people living with HIV and contribute to HIV treatment and prevention worldwide.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.